期刊
NANOSCALE
卷 9, 期 18, 页码 5755-5768出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/c7nr01469d
关键词
-
类别
资金
- ANR (Agence Nationale de la Recherche) [ANR-11-LABX-0021-01]
- Labex SEAM [ANR 11 LABX 086, ANR 11 IDEX 05 02]
- ANR [07-PCV-0031]
- CGI (Commissariat a l'Investissement d'Avenir)
- FEDER
- Conseil Regional de Bourgogne
- INCa (Institut National du Cancer) [POLYNOM-174]
- Canceropole Grand-Est, la Ligue Nationale Contre le Cancer
- foundation ARC (Association pour la Recherche sur le cancer)
Cancer is a worldwide health problem. It is now considered as a leading cause of morbidity and mortality in developed countries. In the last few decades, considerable progress has been made in anti-cancer therapies, allowing the cure of patients suffering from this disease, or at least helping to prolong their lives. Several cancers, such as those of the lung and pancreas, are still devastating in the absence of therapeutic options. In the early 90s, TRAIL (Tumor Necrosis Factor-related apoptosis-inducing ligand), a cytokine belonging to the TNF superfamily, attracted major interest in oncology owing to its selective antitumor properties. Clinical trials using soluble TRAIL or antibodies targeting the two main agonist receptors (TRAIL-R1 and TRAIL-R2) have, however, failed to demonstrate their efficacy in the clinic. TRAIL is expressed on the surface of natural killer or CD8+ T activated cells and contributes to tumor surveillance. Nanoparticles functionalized with TRAIL mimic membrane-TRAIL and exhibit stronger antitumoral properties than soluble TRAIL or TRAIL receptor agonist antibodies. This review provides an update on the association and the use of nanoparticles associated with TRAIL for cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据